Lipogems product treatment increases the proliferation rate of human tendon stem cells without affecting their stemness and differentiation capability

Pietro Randelli, Alessandra Menon, Vincenza Ragone, Pasquale Creo, Sonia Bergante, Filippo Randelli, Laura De Girolamo, Umberto Alfieri Montrasio, Giuseppe Banfi, Paolo Cabitza, Guido Tettamanti, Luigi Anastasia

Research output: Contribution to journalArticle

Abstract

Increasing the success rate of rotator cuff healing remains tremendous challenge. Among many approaches, the possibility of activating resident stem cells in situ, without the need to isolate them from biopsies, could represent valuable therapeutic strategy. Along this line, it has been recently demonstrated that lipoaspirate product, Lipogems, contains and produces growth-factors that may activate resident stem cells. In this study, human tendon stem cells (hTSCs) from the rotator cuff were cocultured in a transwell system with the Lipogems lipoaspirate product and compared to control untreated cells in terms of cell proliferation, morphology, stem cell marker and VEGF expression, and differentiation and migration capabilities. Results showed that the Lipogems product significantly increases the proliferation rate of hTSCs without altering their stemness and differentiation capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during the healing process. Overall, this study supports that directly activating hTSCs with the Lipogems lipoaspirate could represent a new practical therapeutic approach. In fact, obtaining a lipoaspirate is easier, safer, and more cost-effective than harvesting cells from tendon or bone marrow biopsies, expanding them in GMP facility and then reinjecting them in the patient.

Original languageEnglish
Article number4373410
JournalStem Cells International
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Tendons
Stem Cells
Rotator Cuff
Vascular Endothelial Growth Factor A
Therapeutics
Biopsy
Intercellular Signaling Peptides and Proteins
Bone Marrow
Cell Proliferation
Costs and Cost Analysis

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Lipogems product treatment increases the proliferation rate of human tendon stem cells without affecting their stemness and differentiation capability. / Randelli, Pietro; Menon, Alessandra; Ragone, Vincenza; Creo, Pasquale; Bergante, Sonia; Randelli, Filippo; De Girolamo, Laura; Alfieri Montrasio, Umberto; Banfi, Giuseppe; Cabitza, Paolo; Tettamanti, Guido; Anastasia, Luigi.

In: Stem Cells International, Vol. 2016, 4373410, 2016.

Research output: Contribution to journalArticle

@article{ff4be675c16d4e6ebc68806e662bb4ff,
title = "Lipogems product treatment increases the proliferation rate of human tendon stem cells without affecting their stemness and differentiation capability",
abstract = "Increasing the success rate of rotator cuff healing remains tremendous challenge. Among many approaches, the possibility of activating resident stem cells in situ, without the need to isolate them from biopsies, could represent valuable therapeutic strategy. Along this line, it has been recently demonstrated that lipoaspirate product, Lipogems, contains and produces growth-factors that may activate resident stem cells. In this study, human tendon stem cells (hTSCs) from the rotator cuff were cocultured in a transwell system with the Lipogems lipoaspirate product and compared to control untreated cells in terms of cell proliferation, morphology, stem cell marker and VEGF expression, and differentiation and migration capabilities. Results showed that the Lipogems product significantly increases the proliferation rate of hTSCs without altering their stemness and differentiation capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during the healing process. Overall, this study supports that directly activating hTSCs with the Lipogems lipoaspirate could represent a new practical therapeutic approach. In fact, obtaining a lipoaspirate is easier, safer, and more cost-effective than harvesting cells from tendon or bone marrow biopsies, expanding them in GMP facility and then reinjecting them in the patient.",
author = "Pietro Randelli and Alessandra Menon and Vincenza Ragone and Pasquale Creo and Sonia Bergante and Filippo Randelli and {De Girolamo}, Laura and {Alfieri Montrasio}, Umberto and Giuseppe Banfi and Paolo Cabitza and Guido Tettamanti and Luigi Anastasia",
year = "2016",
doi = "10.1155/2016/4373410",
language = "English",
volume = "2016",
journal = "Stem Cells International",
issn = "1687-966X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Lipogems product treatment increases the proliferation rate of human tendon stem cells without affecting their stemness and differentiation capability

AU - Randelli, Pietro

AU - Menon, Alessandra

AU - Ragone, Vincenza

AU - Creo, Pasquale

AU - Bergante, Sonia

AU - Randelli, Filippo

AU - De Girolamo, Laura

AU - Alfieri Montrasio, Umberto

AU - Banfi, Giuseppe

AU - Cabitza, Paolo

AU - Tettamanti, Guido

AU - Anastasia, Luigi

PY - 2016

Y1 - 2016

N2 - Increasing the success rate of rotator cuff healing remains tremendous challenge. Among many approaches, the possibility of activating resident stem cells in situ, without the need to isolate them from biopsies, could represent valuable therapeutic strategy. Along this line, it has been recently demonstrated that lipoaspirate product, Lipogems, contains and produces growth-factors that may activate resident stem cells. In this study, human tendon stem cells (hTSCs) from the rotator cuff were cocultured in a transwell system with the Lipogems lipoaspirate product and compared to control untreated cells in terms of cell proliferation, morphology, stem cell marker and VEGF expression, and differentiation and migration capabilities. Results showed that the Lipogems product significantly increases the proliferation rate of hTSCs without altering their stemness and differentiation capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during the healing process. Overall, this study supports that directly activating hTSCs with the Lipogems lipoaspirate could represent a new practical therapeutic approach. In fact, obtaining a lipoaspirate is easier, safer, and more cost-effective than harvesting cells from tendon or bone marrow biopsies, expanding them in GMP facility and then reinjecting them in the patient.

AB - Increasing the success rate of rotator cuff healing remains tremendous challenge. Among many approaches, the possibility of activating resident stem cells in situ, without the need to isolate them from biopsies, could represent valuable therapeutic strategy. Along this line, it has been recently demonstrated that lipoaspirate product, Lipogems, contains and produces growth-factors that may activate resident stem cells. In this study, human tendon stem cells (hTSCs) from the rotator cuff were cocultured in a transwell system with the Lipogems lipoaspirate product and compared to control untreated cells in terms of cell proliferation, morphology, stem cell marker and VEGF expression, and differentiation and migration capabilities. Results showed that the Lipogems product significantly increases the proliferation rate of hTSCs without altering their stemness and differentiation capability. Moreover, treated cells increase the expression of VEGF, which is crucial for the neovascularization of the tissue during the healing process. Overall, this study supports that directly activating hTSCs with the Lipogems lipoaspirate could represent a new practical therapeutic approach. In fact, obtaining a lipoaspirate is easier, safer, and more cost-effective than harvesting cells from tendon or bone marrow biopsies, expanding them in GMP facility and then reinjecting them in the patient.

UR - http://www.scopus.com/inward/record.url?scp=84955507684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955507684&partnerID=8YFLogxK

U2 - 10.1155/2016/4373410

DO - 10.1155/2016/4373410

M3 - Article

VL - 2016

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-966X

M1 - 4373410

ER -